Author:
Lim Do Hyoung,Kim Hyeong Su,Park Young Suk,Lee Jeeyun,Park Se Hoon,Lim Ho Yeong,Ji Sang Hoon,Park Min Jae,Yi Seong Yoon,An Ji Yeong,Sohn Tae Sung,Noh Jae Hyoung,Bae Jae Moon,Kim Sung,Park Cheol Keun,Kang Won Ki
Abstract
Abstract
Background
Currently, the TNM staging system is a widely accepted method for assessing the prognosis of the disease and planning therapeutic strategies for cancer. Of the TNM system, the extent of lymph node involvement is the most important independent prognostic factor for gastric cancer. The aim of our study is to evaluate the survival and prognosis of gastric cancer patients with LN#12 or #13 involvement only and to assess the impact of anatomic regions of primary gastric tumor on survival in this particular subset of patients.
Methods
Among data of 1,008 stage IV gastric cancer patients who received curative R0 gastrectomy, a total of 79 patients with LN#12 (n = 68) and/or #13 (n = 11) were identified. All patients performed gastrectomy with D2 or D3 lymph node dissection.
Results
In 79 patients with LN#12/13 involvement, the estimated one-, three- and five-year survival rate was 77.2%, 41.8% and 26.6% respectively. When we compared the patients with LN#12/13 involvement to those without involvement, there was no significant difference in OS (21.0 months vs. 25.0 months, respectively; P = 0.140). However, OS was significantly longer in patients with LN#12/13 involvement only than in those with M1 lymph node involvement (14.3 months; P = 0.001). There was a significant difference in survival according to anatomic locations of the primary tumor (lower to mid-body vs. high body or whole stomach): 26.5 vs. 9.2 months (P = 0.009). In Cox proportional hazard analysis, only N stage (p = 0.002) had significance to predict poor survival.
Conclusion
In this study we found that curatively resected gastric cancer patients with pathologic involvement of LN #12 and/or LN #13 had favorable survival outcome, especially those with primary tumor location of mid-body to antrum. Prospective analysis of survival in gastric cancer patients with L N#12 or #13 metastasis is warranted especially with regards to primary tumor location.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference28 articles.
1. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, Seo SW, Kim KY, Lee SY, Kong IS, et al: National cancer incidence for the year 2002 in Korea. Cancer Res Treat. 2007, 39 (4): 139-149. 10.4143/crt.2007.39.4.139.
2. Karpeh MS, Leon L, Klimstra D, Brennan MF: Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000, 232 (3): 362-371. 10.1097/00000658-200009000-00008.
3. Siewert JR, Bottcher K, Stein HJ, Roder JD: Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998, 228 (4): 449-461. 10.1097/00000658-199810000-00002.
4. Hermanek P, Sobin LH: UICC TNM Classification of Malignant Tumors. 1987, Belin: Springer, 4
5. Oliver HB, Donald EH, Robert VP, Hutter BJ, Kennedy : Manual for Staging of Cancer, American Joint Committee on Cancer, 4th ed. 1992, Philadelphia: JB Lippincott
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献